PTC Therapeutics (PTCT) said Friday that the European Commission has adopted the recommendation of the Committee for Medicinal Products for Human Use to not renew Translarna's marketing authorization for nonsense mutation Duchenne muscular dystrophy.
The commission indicated that under EU Directive 2001/83, individual member states in the European Union can still allow continued use of Translarna, the company said.
PTC Therapeutics said it plans to work on a country-by-country basis to continue marketing
Translarna, or ataluren, for Duchenne muscular dystrophy in the region.
Price: 54.98, Change: -0.01, Percent Change: -0.02
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。